Abstract: Compositions and methods for the treatment of pruritic ani and anal fissures are described. The compositions include one or more of Calamine (USP) or zinc oxide (ZnO), aluminum hydroxide (Al(OH)3) or kaolin, glycerin, and menthol (or any compound which activates the menthol receptor (TRPM8)). The composition does not contain any hydrocarbon-based pharmaceutical carrier such as petroleum jelly, white petrolatum, mineral oil, hard paraffin, soft paraffin, microcrystalline wax, ceresine, or hard fats. Methods of treating pruritic ani and anal fissures by topical application(s) of the compositions to affected perianal or anal epidermis are also described.

Abstract: Suspensions of pump inhibitors (PPIs) are disclosed. The suspension may include a PPI, a copolymer of ethylene oxide and propylene oxide; simethicone emulsion; Sodium Bicarbonate; and Sodium Citrate, USP (Dihydrate). The suspensions have desirable viscosities and enhanced stability.

Abstract: Silica-including microcapsule resin particles including an outer shell constituted of a crosslinked polymer and a cavity partitioned with the outer shell, in which the silica-including microcapsule resin particles contain inside the cavity a porous structure in which silica particles are mutually connected, and have a volume average particle diameter of 0.5 to 100 ?m.

Abstract: Provided herein is an amorphous compound represented by Formula (I): and compositions thereof, which are useful in the treatment of disorders related to the activity of the c-KIT and PDGFR? kinases, and oncogenic forms thereof.

Abstract: The disclosure relates, among others, to methods for preparing pharmaceutical compositions that can be provided to the subject in oral form, comprising as an active ingredient: a protein with a mass of 10 kilodalton or more, a nucleic acid molecule of 15 nucleotides or more, or a combination thereof. The one or more active ingredients are distributed in particles in a way that facilitates the uptake of the particles by the intestine and the release of the active ingredient(s) into the blood stream.

Abstract: Provided is an injectable implant configured to fit at or near a bone defect to promote bone growth, the injectable implant comprising lyophilized demineralized bone matrix (DBM) being in fiber and particle forms; alginate; and a liquid carrier, wherein the DBM is in an amount of about 20 wt. % to about 40 wt. % of a total weight of the injectable implant, the alginate is in an amount of from about 3 wt. % to about 10 wt. % of the total weight of the injectable implant, and the liquid carrier is in an amount from about 50 wt. % to about 70 wt. % of the total weight of the injectable implant. A moldable implant and methods of making the implants are further provided.

Abstract: A water-dissolvable nicotine tablet is disclosed, the nicotine tablet comprising at least a first compressed module and a second compressed module, wherein the first compressed module is an FDT-module and comprises nicotine, alkaline pH regulating agent, and disintegrant, and, wherein the second compressed module is a lozenge-module and comprises acidic pH regulating agent. Also, a method of manufacturing a nicotine tablet is disclosed.

Abstract: A preparation containing saxagliptin having improved stability and a method for producing the same are provided. According to an embodiment of the present invention, a preparation containing saxagliptin including a plain tablet part containing one or more first additive agent selected from a group consisting of D-mannitol, lactose, anhydrous lactose, and anhydrous dibasic calcium phosphate, the plain tablet part containing less than 35% by weight of crystalline cellulose with respect to 100% by weight of the plain tablet part, and a film coating part in contact with the plain tablet part and containing saxagliptin, a salt thereof, or a hydrate thereof, and a method for producing the same are provided.

Abstract: A cosmetic composition is provided. The cosmetic composition includes Astrocaryum vulgare oil and/or butter, which is useful in the production and/or protection against degradation of hyaluronic acid in the skin. Also provided are the process for the production of the cosmetic composition and related uses and methods.

Abstract: A method for producing a powderized cannabis oil includes providing a cannabis oil; dissolving the cannabis oil in an alcohol to form a solution; mixing amylose, amylopectin, or a combination thereof into the solution; and evaporating the alcohol.

Abstract: A gastroretentive, sustained-release dosage form including 5-hydroxytryptophan (5-HTP) as an active ingredient and low-dose carbidopa is described. For example, the dosage form can be provided as a bilayer tablet comprising a swelling layer and a modified release layer, where the 5-HTP and carbidopa are both included in the modified release layer. The dosage form provides for essentially parallel release of the 5-HTP and the carbidopa with, for instance, release of 80% of the 5-HTP and carbidopa at about 5 hours to about 12 hours.

Abstract: Thyroid hormone oral dosage forms and methods of making and using the thyroid hormone oral dosage forms are disclosed.

Abstract: A dosage form contains a biologically active ingredient for treating or preventing a disease in the animal or human body, where the treatment or prevention requires release of 50% or more of the biologically active ingredient in the small intestine within the pH range from 3 to 5.5. The dosage form contains: a) a core, containing the biologically active ingredient; b) an intermediate coating layer (ICL) onto or above the core, containing an alkaline agent; and c) an enteric coating layer (ECL) onto or above the intermediate coating layer, containing an enteric polymer. The relation of the alkaline agent to the enteric polymer is 5 to 95% when calculated by the formula: quantity ? of ? alkaline ? agent ? in ? grams ? in ? the ? I ? C ? L × 100 ( quantity ? of ? alkaline ? agent ? in ? grams ? in ? the ? I ? C ? L + quantity ? of ? enteric ? polymer ? in ? grams ? in ? the ? E ? C ? L ) .

Abstract: A composition comprises a therapeutically effective oral pharmaceutical dosage form. The dosage form includes an aqueous carrier material having an acidic pH and a plurality of individual pellets having a first dose of melatonin therein. The individual pellets comprises (i) a solid core; (ii) an active coating over the solid core, the active coating including melatonin and a hydrophilic binder; and (iii) an enteric coating over the active coating. A dissolution pH of the enteric coating is higher than the acidic pH of the aqueous carrier material.

Abstract: The present invention provides oral care compositions. The compositions may be provided in a solid form, such as a film. The compositions can comprise one or more film forming polymers, one or more bioadhesive agents, one or more plasticizers, benzocaine (and optionally one or more further active ingredients), one or more polymeric solvents, and an aqueous solvent. The oral care composition can be a solid or semi-solid composition up to a temperature of at least 40° C. Methods of providing such an oral care compositions are also provided herein.

Abstract: The present invention includes compositions and methods for providing a therapeutically acceptable dose of an active pharmaceutical agent for once a day delivery of the active pharmaceutical compound in an amount effective to treat at least one of: Sjogren's syndrome, Xerostomia, dry mouth, hypo-salivation, or dental carries due to reduced or compromised salivation, wherein both the peak and trough times in the blood level at 8 hours is greater than 25% of the peak value in the blood level concentration.

Abstract: The present application relates to a method for preparing a pharmaceutical composition, the method comprising providing pharmaceutical compound having a solubility in water of 1 mg/ml or less at 25° C. in a solvent enabling solubilizing the pharmaceutical compound at least partly into the solvent, providing an aqueous dispersion of nanostructured cellulose, and combining the pharmaceutical compound with the aqueous dispersion of nanostructured cellulose in an anti-solvent process to provide nanosized pharmaceutical particles having an average diameter of 50 nm or less, to provide a pharmaceutical composition. The present application also provides pharmaceutical composition, and use of the pharmaceutical composition.

Abstract: A sunscreen composition comprised of one or more sunscreen active agents encapsulated in a cellulose derived capsule wherein the composition can contain one or more additional agents. A sunscreen composition can be mixed with a body wash, an after shower body lotion, a shampoo, a conditioner, a soap, a gel, a hand sanitizer, a cream, a spray, a mouse, a lotion, an ointment, a make-up product, a lip balm, a hair spray product, an arachnid/insect repellent or a medicinal product.

Abstract: Compositions and methods for the treatment of pruritic ani and anal fissures are described. The compositions include one or more of Calamine (USP) or zinc oxide (ZnO), aluminum hydroxide (Al(OH)3) glycerin, and menthol (or any compound which activates the menthol receptor (TRPM8)). The composition does not contain (or contains a limited amount, such as less than 10%) of a hydrocarbon-based pharmaceutical carrier such as petroleum jelly, white petrolatum, mineral oil, hard paraffin, soft paraffin, microcrystalline wax, or ceresine. Methods of treating pruritic ani and anal fissures by topical application(s) of the compositions to affected perianal or anal epidermis are also described.

Abstract: The present invention concerns a method for obtaining an implantable cartilage gel for tissue repair of hyaline cartilage, comprising particles of chitosan hydrogel and cells that are capable of forming hyaline cartilage, said method comprising a step for amplification of primary cells in a three-dimensional structure comprising particles of physical hydrogel of chitosan or a chitosan derivative, then a step for re-differentiation and induction of the synthesis of extracellular matrix by said amplified cells, in the same three-dimensional structure, wherein said cells are primary articular chondrocytes and/or mesenchymal stem cells differentiated into chondrocytes. The present invention also concerns the cartilage gel obtained thereby, and its various uses for cartilage repair following a traumatic lesion or an osteoarticular disease such as osteoarthritis.